Literature DB >> 16514715

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

Cevher Ozcan, Stuart J Wong, Parameswaran Hari.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16514715

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  62 in total

1.  Diagnostic uncertainty around seizures in advanced malignancy.

Authors:  Demiana Lenzi Lewis-Hanna; Gurjeet Pamma
Journal:  BMJ Case Rep       Date:  2011-12-21

Review 2.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

3.  Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab.

Authors:  Ghassan El Maalouf; Emmanuel Mitry; Alexis Lacout; Astrid Lièvre; Philippe Rougier
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

4.  Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.

Authors:  Franck Bürki; Kattalin Badie; Philippe Bartoli; Pascale Bernard; Jean Louis Montastruc; Haleh Bagheri
Journal:  Br J Clin Pharmacol       Date:  2008-02-15       Impact factor: 4.335

Review 5.  Neurologic complications of antitumor antibody therapies.

Authors:  Teri N Kreisl
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

6.  Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Authors:  Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin
Journal:  Invest New Drugs       Date:  2014-05-23       Impact factor: 3.850

Review 7.  Management of VEGF-Targeted Therapy-Induced Hypertension.

Authors:  Stefano Caletti; Anna Paini; Maria Antonietta Coschignano; Carolina De Ciuceis; Matteo Nardin; Roberto Zulli; Maria Lorenza Muiesan; Massimo Salvetti; Damiano Rizzoni
Journal:  Curr Hypertens Rep       Date:  2018-06-29       Impact factor: 5.369

8.  Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.

Authors:  Erkan Dogan; Sercan Aksoy; Cagatay Arslan; Didem S Dede; Kadri Altundag
Journal:  Med Oncol       Date:  2010-12       Impact factor: 3.064

9.  A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Authors:  R J Schilder; M W Sill; H A Lankes; M A Gold; R S Mannel; S C Modesitt; P Hanjani; A J Bonebrake; A K Sood; A K Godwin; W Hu; R K Alpaugh
Journal:  Gynecol Oncol       Date:  2013-01-13       Impact factor: 5.482

10.  The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis.

Authors:  B K Kleinschmidt-DeMasters; Denise M Damek
Journal:  J Neurooncol       Date:  2009-07-16       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.